The Pentagon has rolled out mandatory testosterone screening for active-duty and reserve service members aged 30 and up, a new policy meant to protect soldiers’ long-term health and sharpen readiness. This article walks through what the guidance requires, how men and women are affected differently, the medical reasoning offered by the department, and the concerns some experts have raised. The change was authorized by Defense Secretary Pete Hegseth and takes effect immediately for the specified age group.
Defense leaders are pitching this as a straightforward readiness move that helps troops stay fit for duty and life after service, and the goal is simple: stronger, healthier forces. Secretary Pete Hegseth authorized the screening and framed it as ensuring “you have the right testosterone levels to operate at your absolute best.” From a conservative view, checking the basics for mission performance is commonsense stewardship of our people and taxpayer resources.
The Pentagon’s guidance makes testing mandatory for men 30 and older, while younger men will be tested only if they ask for it or medical staff spot warning signs. The policy is presented as standardized care rather than ad hoc screening, and it includes pathways for follow-up evaluation when a blood test shows low levels. Officials argue that catching hormonal issues early prevents bigger readiness problems down the road.
For men diagnosed with low testosterone, the guidance opens the door to further evaluation and, when clinically warranted, voluntary hormone replacement therapy under medical supervision. The emphasis is on clinical appropriateness and consent, not blanket prescribing or forced treatments. Importantly, testosterone use for non-medical purposes, including performance enhancement without a doctor’s prescription, remains prohibited in the military.
The new rules also explain the biology behind the move: testosterone surges during puberty to build muscle, body hair and sperm production, and then gradually declines starting in the 30s. That decline is a normal part of aging, but it can affect energy, strength and recovery—qualities critical to service members. Knowing where individuals sit on that curve helps clinicians tailor care and keep units mission-ready.
Women are treated differently under the guidance: routine testosterone blood tests are not required, but medical staff will screen for symptoms like persistent fatigue or disrupted menstrual cycles. Those signs can point to broader hormonal dysregulation or conditions such as low-energy availability and relative energy deficiency in sport, which can hurt performance and health. The policy includes criteria for when hormonal evaluation is appropriate without making testing a universal mandate for female service members.
The guidance also spells out when off-label testosterone might be considered for women, particularly postmenopausal women with unusually low sexual desire, aiming to constrain prescriptions to carefully evaluated cases. That narrow scope tries to balance treating genuine medical problems while avoiding indiscriminate use. The military makes clear that medically supervised therapy is distinct from illicit performance enhancement and will be managed accordingly.
Officials say the point of these standardized screening and treatment pathways is to identify and manage hormonal and energy-availability issues that could undermine readiness. From a Republican perspective, this is about practical prevention: address problems early to keep units strong and reduce downstream costs and deployments compromised by treatable conditions. Still, some endocrinologists and clinicians caution that broad testing could spark unnecessary or even harmful treatments because the evidence is limited on whether universal screening improves outcomes in uniformed populations.
The Food and Drug Administration plans to convene experts later this month to discuss medical uses of testosterone, a step that could inform how the policy is implemented and what testing thresholds make sense clinically. The debate now is between a results-oriented readiness approach favored by many conservatives and a cautious medical community urging proof that widespread screening does more good than harm. For commanders and clinicians on the ground, the immediate task is practical: follow the new guidance, protect service members, and monitor outcomes so policy stays tied to evidence and mission needs.
